For Industry & Investors

NYU has a commitment to translational research and a strong track record in seeing its discoveries successfully commercialized to benefit the public. More than twenty biomedical products have come to market based on NYU technologies, including drugs to treat cancers, rheumatoid arthritis, and psoriasis, diagnostics to help guide HIV therapy, MRI technology, orthopaedic and dental implants, stent technology, monitoring equipment, and other device technologies. Numerous additional products are in clinical trials by NYU licensees, including drugs for cancers, heart disease, Alzheimer’s Disease, Parkinson’s Disease, diabetic complications, and malaria. Agricultural technologies to improve crop yields for food and biofuels have also been commercially developed, as have numerous electronics and software technologies, including integrated circuit, touch screen, animation, and customer relations management (CRM) systems.

The Office actively seeks commercial partners to develop NYU technologies, and works to establish mutually beneficial long-term relationships. Almost 60% of NYU patents have been licensed to companies for development and commercialization. Over the past five years, NYU has ranked first among all U.S. universities in income from technology licensing, which is plowed back into further research. Activity has continued to increase, with the number of inventions generated by NYU faculty each year having more than doubled over the past 8 years, and the number of license agreements signed annually having more than tripled.